MCID: INH001
MIFTS: 42

Inhalation Anthrax

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Inhalation Anthrax

MalaCards integrated aliases for Inhalation Anthrax:

Name: Inhalation Anthrax 12 15
Inhalational Anthrax 59 73
Respiratory Anthrax 12 59
Pulmonary Anthrax 12 59
Respiratory Anthrax Disease 59
Inhalation Anthrax Disease 59
Wool-Sorters' Disease 12
Woolsorters' Disease 12

Characteristics:

Orphanet epidemiological data:

59
inhalational anthrax
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:0050160
Orphanet 59 ORPHA247257
ICD10 via Orphanet 34 A22.1
UMLS via Orphanet 74 C0155866
ICD10 33 A22.1
UMLS 73 C0155866

Summaries for Inhalation Anthrax

Disease Ontology : 12 An anthrax disease that results in infection located in lung lymph nodes brought on by breathing in the spores of the bacteria Bacillus anthracis. The first symptoms of inhalation anthrax are like cold or flu symptoms and can include a sore throat, mild fever and muscle aches. Later symptoms include cough, chest discomfort, shortness of breath, tiredness and muscle aches.

MalaCards based summary : Inhalation Anthrax, also known as inhalational anthrax, is related to anthrax disease and influenza. An important gene associated with Inhalation Anthrax is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Uptake and actions of bacterial toxins. The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include lung lymph nodes, lung and lymph node, and related phenotypes are abnormality of the sweat gland and fever

Related Diseases for Inhalation Anthrax

Diseases related to Inhalation Anthrax via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 anthrax disease 30.6 ANTXR1 ANTXR2 TLR9
2 influenza 10.2
3 mucositis 10.0
4 pneumonia 10.0
5 cholera 9.8
6 mediastinitis 9.8
7 chronic granulomatous disease 9.2 NCF4 TLR9

Graphical network of the top 20 diseases related to Inhalation Anthrax:



Diseases related to Inhalation Anthrax

Symptoms & Phenotypes for Inhalation Anthrax

Human phenotypes related to Inhalation Anthrax:

59 32 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the sweat gland 59 32 hallmark (90%) Very frequent (99-80%) HP:0000971
2 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
3 epigastric auras 59 32 hallmark (90%) Very frequent (99-80%) HP:0011159
4 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
5 confusion 59 32 frequent (33%) Frequent (79-30%) HP:0001289
6 vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002013
7 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
8 incomprehensible speech 59 32 frequent (33%) Frequent (79-30%) HP:0002546
9 hypotension 59 32 frequent (33%) Frequent (79-30%) HP:0002615
10 internal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0011029
11 sepsis 59 32 frequent (33%) Frequent (79-30%) HP:0100806
12 dyspnea 59 Frequent (79-30%)

Drugs & Therapeutics for Inhalation Anthrax

Drugs for Inhalation Anthrax (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
2 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
3 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
4 Antitoxins Phase 4
5
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 77-92-9 311
6
Glycine Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 56-40-6 750
7 Citrate Nutraceutical Phase 2, Phase 3,Phase 1
8
Ciprofloxacin Approved, Investigational Phase 1 85721-33-1 2764
9
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
10 gamma-Globulins Phase 1
11 Immunoglobulins, Intravenous Phase 1
12 Rho(D) Immune Globulin Phase 1
13 Anti-Bacterial Agents Phase 1
14 Anti-Infective Agents Phase 1
15 Cytochrome P-450 CYP1A2 Inhibitors Phase 1
16 Cytochrome P-450 Enzyme Inhibitors Phase 1
17 Topoisomerase Inhibitors Phase 1
18
Diethylenetriamine Phase 1 111-40-0 8111
19 Pharmaceutical Solutions Phase 1

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis Not yet recruiting NCT03088111 Phase 4
2 An Open Label, Phase IV Study Evaluating the Clinical Benefit, Safety and Pharmacokinetics of Raxibacumab in Subjects Exposed to Bacillus Anthracis Not yet recruiting NCT02177721 Phase 4
3 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection Completed NCT02016963 Phase 2, Phase 3
4 Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum Completed NCT00448253 Phase 1
5 Monoclonal Antibody for Treatment of Inhalation Anthrax Completed NCT00138411 Phase 1 Ciprofloxacin 500 mg;ETI-204 (Anthim)
6 Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers Completed NCT01952444 Phase 1
7 Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers Completed NCT01932437 Phase 1
8 Safety, Tolerability and PK of Repeat Administration of IV ETI-204 Completed NCT01932242 Phase 1
9 A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers Completed NCT01929226 Phase 1
10 Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects Completed NCT01265745 Phase 1 Normal Saline for Injection
11 A Phase 4 Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients Not yet recruiting NCT03569553 AIGIV

Search NIH Clinical Center for Inhalation Anthrax

Genetic Tests for Inhalation Anthrax

Anatomical Context for Inhalation Anthrax

The Foundational Model of Anatomy Ontology organs/tissues related to Inhalation Anthrax:

19
Lung Lymph Nodes

MalaCards organs/tissues related to Inhalation Anthrax:

41
Lung, Lymph Node, Neutrophil, B Cells

Publications for Inhalation Anthrax

Articles related to Inhalation Anthrax:

(show top 50) (show all 158)
# Title Authors Year
1
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model. ( 28696235 )
2017
2
Protection against inhalation anthrax by immunization with<i>Salmonella enterica serovar Typhi</i>Ty21a stably producing protective antigen of<i>Bacillus anthracis</i>. ( 29263873 )
2017
3
Development of a Zealand white rabbit deposition model to study inhalation anthrax. ( 26895308 )
2016
4
A case report of inhalation anthrax acquired naturally. ( 26939756 )
2016
5
Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection. ( 26438506 )
2015
6
Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax. ( 25454087 )
2015
7
Antitoxin Treatment of Inhalation Anthrax: A Systematic Review. ( 26690378 )
2015
8
Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration &amp;quot;Animal Rule&amp;quot;. ( 26648915 )
2015
9
Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA. ( 24447456 )
2014
10
Investigation of inhalation anthrax case, United States. ( 24447835 )
2014
11
The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax. ( 23742651 )
2013
12
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. ( 23979731 )
2013
13
Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection. ( 23787486 )
2013
14
Modeling low-dose mortality and disease incubation period of inhalational anthrax in the rabbit. ( 23567649 )
2013
15
Pathology and pathophysiology of inhalational anthrax in a guinea pig model. ( 23357384 )
2013
16
Quantitative models of the dose-response and time course of inhalational anthrax in humans. ( 24058320 )
2013
17
Inhalational anthrax in a vaccinated soldier. ( 23813313 )
2013
18
Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax. ( 23283638 )
2013
19
Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment. ( 22837095 )
2012
20
Sverdlovsk revisited: pulmonary pathology of inhalational anthrax versus anthraxlike Bacillus cereus pneumonia. ( 22372894 )
2012
21
Inhalational anthrax (Ames aerosol) in naA^ve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia. ( 22919678 )
2012
22
Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax. ( 22025514 )
2012
23
Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax. ( 22526673 )
2012
24
Dissemination bottleneck in a murine model of inhalational anthrax. ( 22753373 )
2012
25
A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. ( 22933399 )
2012
26
Lung B cells promote early pathogen dissemination and hasten death from inhalation anthrax. ( 22472773 )
2012
27
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. ( 22695155 )
2012
28
Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys. ( 22172509 )
2012
29
A dynamic dose-response model to account for exposure patterns in risk assessment: a case study in inhalation anthrax. ( 21068030 )
2011
30
Key aspects of the molecular and cellular basis of inhalational anthrax. ( 21816231 )
2011
31
Antibody responses to a spore carbohydrate antigen as a marker of nonfatal inhalation anthrax in rhesus macaques. ( 21389148 )
2011
32
Post-exposure therapy of inhalational anthrax in the common marmoset. ( 21530184 )
2011
33
Public response to an anthrax attack: reactions to mass prophylaxis in a scenario involving inhalation anthrax from an unidentified source. ( 21819225 )
2011
34
Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax. ( 20956592 )
2011
35
Modeling the host response to inhalation anthrax. ( 21295589 )
2011
36
Rapidly progressive, fatal, inhalation anthrax-like infection in a human: case report, pathogen genome sequencing, pathology, and coordinated response. ( 21882964 )
2011
37
Raxibacumab for inhalational anthrax: an effective specific therapeutic approach? ( 20450444 )
2010
38
A synthetic peptide vaccine directed against the 2A92-2A93 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. ( 20696862 )
2010
39
Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. ( 21124994 )
2010
40
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. ( 19858256 )
2010
41
Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. ( 20479237 )
2010
42
Influence of particle size on the pathology and efficacy of vaccination in a murine model of inhalational anthrax. ( 20798216 )
2010
43
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model. ( 20047912 )
2010
44
Public health and environmental response to the first case of naturally acquired inhalational anthrax in the United States in 30 years: infection of a new york city resident who worked with dried animal hides. ( 20357604 )
2010
45
Pathology of inhalational anthrax animal models. ( 20656900 )
2010
46
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. ( 19207098 )
2009
47
Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. ( 19114543 )
2009
48
A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. ( 19099484 )
2009
49
The physiologic responses of Dutch belted rabbits infected with inhalational anthrax. ( 19619416 )
2009
50
Protecting against future shock--inhalational anthrax. ( 19587345 )
2009

Variations for Inhalation Anthrax

Expression for Inhalation Anthrax

Search GEO for disease gene expression data for Inhalation Anthrax.

Pathways for Inhalation Anthrax

GO Terms for Inhalation Anthrax

Cellular components related to Inhalation Anthrax according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 8.92 ANTXR1 ANTXR2 NCF4 TLR9

Biological processes related to Inhalation Anthrax according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 toxin transport GO:1901998 8.96 ANTXR1 ANTXR2
2 reproductive process GO:0022414 8.62 ANTXR1 ANTXR2

Molecular functions related to Inhalation Anthrax according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 8.8 ANTXR1 ANTXR2 TLR9

Sources for Inhalation Anthrax

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....